UC Davis School of Veterinary Medicine is running a clinical trial to assess a new drug in addition to present treatment of osteosarcoma.
The average survival of dogs who have undergone amputation to treat the primary tumor followed by chemotherapy is 10 - 12 months. The purpose of the study is to evaluate an oral drug which, added to the current protocol, should improve the outcome of the standard therapy and inhibit cancer progression.
The drug being tested is rapamycin, originally used to prevent transplant rejection in human medicine. So it happens that it's also being studied whether or not it can extend dogs' lives. It's an immunosuppressive so its use to inhibit cancer seems rather anti-intuitive. However, preliminary studies indicate that it can work as an anti-tumor agent.
The study will enroll 160 dogs nationwide. Only dogs diagnosed with osteosarcoma who have not yet received any therapy are accepted.
For more information or to enroll, contact The Oncology Clinical Trial Coordinators via email (email@example.com) or phone (530-752-0125 or 530-752-9759)
US Davis Veterinary Medicine Clinical Trials: Oncology